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A B S T R A C T
Autoimmune diseases such as rheumatoid arthritis (RA) cause significant morbidity and
loss of productivity. Many potent conventionally used drugs are available for these dis-
eases, but their prolonged use is accompanied by severe adverse effects besides a high cost.
Therefore, there is an unmet need for effective but less expensive medications for RA and
other autoimmune diseases. Natural plant products belonging to the traditional systems
of medicine, such as the traditional Chinese medicine and Indian Ayurvedic medicine, offer
a vast and promising resource in this regard. However, herbal medicinal products are often
poorly characterized for their composition as well as mechanisms of action.We review here
the results of our systematically performed studies aimed at defining the anti-arthritic ac-
tivity of three herbal extracts, namely,modified Huo-luo-xiao-ling dan (HLXL),Celastrus aculeatus
Merr., and polyphenolic fraction of green tea (Camellia sinensis), as well as a purified
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compound Celastrol, a bioactive component of Celastrus. Specifically, we examined the
effects of these herbal products on the immunological, biochemical and molecular
biological effector pathways in autoimmune arthritis.We have also reviewed here related
studies on these herbal products by other investigators. Taken together, we suggest
further testing of these herbal products in RA patients.
© 2016 Production and hosting by Elsevier B.V. on behalf of Shenyang Pharmaceutical
University. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Autoimmune diseases result from deregulated immune re-
sponses that attack the body’s own tissues contrary to their
traditional role in protecting the host against external infec-
tious agents. Complex interplays among genetic and
environmental factors are involved in the pathogenesis of au-
toimmunity [1,2]. Cell-mediated and/or antibody-mediated
effector responses contribute to autoimmune inflammation and
tissue damage [3,4]. These processes can either affect mul-
tiple organs (systemic autoimmunity) or be limited primarily
to one organ (organ-specific autoimmunity) [3,5]. Rheuma-
toid arthritis (RA), multiple sclerosis (MS), systemic lupus
erythematosus (SLE), and type 1 diabetes (T1D) are examples
of the major human autoimmune diseases [3,5]. In general, the
prevalence of these diseases is relatively higher in the devel-
oped countries compared to that in the developing countries.
For example, the prevalence of RA is estimated to be approxi-
mately 1% in the United States compared to about 0.2–0.3% in
China and a subset of population from rural South Africa, and
the female to male ratio for RA is 2–3:1 [6]. Uncontrolled au-
toimmune pathology may result in severe disabilities and/or
deformities, and loss of organ function. Due to their chronic
nature, autoimmune diseases impose a heavy economical, psy-
chological and social burden on the society.Therefore, effective
safe therapeutic agents, and treatment regimen are critical to
the management of patients with autoimmunity.The remain-
ing section of this article will mostly cover RA and its
experimental models, with some examples of other autoim-
mune diseases, where needed.
RA affects people all over the world, with geographical dif-
ferences in prevalence [7–9]. Major advances have been made
in the treatment of RA over the past couple decades. Non-
steroidal anti-inflammatory drugs (NSAIDs) (e.g., aspirin,
ibuprofen, and naproxen), corticosteroids, and disease-modifying
anti-rheumatic drugs (DMARDs) (e.g., methotrexate,
sulfasalazine, and leflunomide) represent conventionally used
(allopathic) drugs for the management of RA [10–12]. Recent
additions to this arsenal against RA are the biologics com-
posed of cytokine-/cytokine receptor-based drugs that belong
to the DMARDs category [12]. The biologics work by binding
either to a particular cytokine (e.g., TNF-α, IL-6, or IL-17) and
neutralizing its function or to the cytokine receptor (e.g.,TNF-α
receptor) and preventing the binding of the endogenous
cytokine ligand to its cognate receptor. Consequently, biolog-
ics are quite potent and effective in controlling the progression
of RA. However, their prolonged use is associated with severe
adverse reactions, including severe infections. Furthermore,
these mainstream drugs, particularly biologics, are very ex-
pensive, and it is very difficult for many patients in the
developing countries to afford them.Therefore, there is a con-
tinued search for relatively less expensive yet effective
alternatives to conventional drugs for RA therapy. In this
context, natural plant products constitute a vital and prom-
ising resource for identifying new therapeutic agents for RA
that meet these criteria.
Plant products have been the source of a large number of
bioactive compounds with therapeutic potential, of whichmany
eventually have been developed into drugs that are con-
sumed worldwide for diverse disorders, including inflammatory
and autoimmune diseases, infectious diseases, and cancer
[13–19]. Furthermore, a variety of herbal products belonging to
the traditional systems of medicine are either already being
used by patients with autoimmune diseases including RA, with
or without the primary physician’s knowledge, or are under
investigation for their therapeutic potential [13–15,18–20]. Such
medicinal herbs belong to the traditional Chinese medicine
(TCM), Japanese traditional medicine (Kampo), Egyptian and
other African traditional medicine, Indian Ayurvedic medi-
cine, and other systems.
Adjuvant-induced arthritis (AA) is a well-established ex-
perimental model of human RA [21,22]. The AA model has
extensively been used for studies on the pathogenesis of au-
toimmune arthritis, for screening of potential anti-arthritic
compounds, and for defining the mechanisms of action of such
compounds. AA can be induced in Lewis rats (RT.1l) by subcu-
taneous immunization with heat-killed Mycobacterium
tuberculosis H37Ra (Mtb). The disease appears in about 10–
12 days and it affects all paws. However, generally the disease
is more severe in the hind paws than the fore paws. The se-
verity of clinical arthritis can be assigned a semi-quantitative
grade on a scale of 0 (no disease) to 4 (severe arthritis) on the
basis of erythema and swelling of the paws as described in
detail elsewhere [21,22]. Such grading is helpful in quantify-
ing the effect of natural products on the severity of arthritis.
An alternativemethod used by some investigators is to measure
the volume of the swollen paws by using an equipment called
Plethysmograph.
In our laboratory, we have tested 3 herbal extracts (Huo-
luo-xiao-ling dan (HLXL), Celastrus, and Green tea) and one
purified compound (Celastrol) derived from one of them
(Celastrus) in the rat AA model of RA. We also examined the
influence of these herbal products on various immunologi-
cal, biochemical and molecular parameters associated with the
disease process in RA (Fig. 1).We have discussed below details
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of HLXL as a prototypic TCM herbal formula as an anti-
arthritic agent [23–25].This is followed by description of salient
features of Celastrus extract [21,22,26,27], green tea polyphe-
nolic extract [28], and Celastrol [22,26,27] for their suppressive
effect on arthritis.
2. Anti-arthritic herbal extracts and their
mechanisms of action
2.1. Huo-luo-xiao-ling dan (HLXL)
HLXL is a TCM and is a multi-herbal formulation.We tested a
modified version of original HLXL, and it consisted of 11 herbs
(Chinese name, botanical names, and family names)
[23–25,29–31]: Ruxiang (Boswellia carterii Birdw.), Qianghuo
(Notopterygium incisum Ting ex H.T. Chang), Danggui (Angelica
sinensis (Oliv.) Diels), Chishao (Paeonia lactiflora Pall.), Gancao
(Glycyrrhiza uralensis Fisch.), Yanhusuo (Corydalis yanhusuoW.T.
Wang.), Danshen (Salvia miltiorrhiza Bge.), Chuanxiong (Ligusticum
chuanxiong S.H. Qiu.), Qinjiao (Gentiana macrophylla Pall.), Guizhi
(Cinnamomum cassia Presl.), and Duhuo (Angelica pubescens
Maxim). The precise composition including percent weight of
individual herbs is described in our earlier studies [23–25,29–31].
This herbal mixture was thoroughly characterized by high per-
formance liquid chromatography (HPLC) andmass spectrometry
(MS) [24,25,29]. Defined bioactive components belonging to
several herbs in themixture were used as biomarkers for quality
control to ensure batch-to-batch variations. Furthermore, the
mixture was prepared following the guidelines of good manu-
facturing practices, and the toxicity of the mixture was
systematically assessed [24,25,29]. This also formed the basis
of the dose of HLXL tested in our study in arthritic rats.
Arthritic Lewis rats were treated with HLXL (2.3 g/kg/day)
administered as a suspension in water and given by a gavage
needle attached to a syringe [23,25,30,31]. The treatment was
started at the onset of AA and continued throughout the period
of study. Arthritic severity was graded using a clinical scoring
system.The effects on clinical aspects of the disease were vali-
dated by histological analysis of arthritic paws.The paw sections
were also examined for histomorphometric parameters to
assess bone and cartilage damage in the joints [30]. The drain-
ing lymph nodes, splenic lymphoid cells, and sera of these rats
were collected and tested for cytokines, chemokines, nitric oxide
(NO), and other mediators of inflammation and bone damage
[25,30]. Finally, the draining lymph node cells (LNC) were tested
for HLXL-induced changes in gene expression using microarray
analysis [31].
Our results [23,25,30,31] showed that HLXL was effective in
suppressing both clinical and histological features of arthri-
tis. This reduction in disease severity was associated with a
decrease in several mediators of inflammation, namely, pro-
inflammatory cytokines interleukin-1β (IL-1β), IL-6, and IL-17;
serum nitric oxide and matrix metalloproteinase-9 (MMP-9);
antibodies to mycobacterial heat-shock protein 65 (Bhsp65);
chemokines (regulated upon activation, normal T cell ex-
pressed, and secreted (RANTES), monocyte chemotactic
protein-1 (MCP-1), macrophage inflammatory protein-1α
(MIP-1α), and growth regulated oncogene/keratinocyte
chemoattractant (GRO/KC)) [30]; and mediators of bone re-
modeling (e.g., receptor activator of nuclear factor-κB ligand
(RANKL), osteoprotegerin (OPG), and osteopontin (OPN)) [23].
Microarray analysis of the draining LNC revealed distinct pat-
terns of gene expression in HLXL-treated vs. vehicle-treated
arthritic rats [31]. The former showed 84 differentially ex-
pressed genes (DEG) (64 upregulated and 20 downregulated),
whereas the latter displayed 120 such genes (94 upregulated
and 26 downregulated).The two groups of rats shared 62 genes
(45 upregulated and 17 downregulated). Several pathways as-
sociated with arthritis were represented in the genes that
showed altered expression.These include metabolism, immune
response, inflammation, cellular proliferation and apoptosis.
Taken together, these results validated the mechanistic aspects
of the anti-arthritic activity of HLXL.
Comparative pharmacokinetic studies in normal and ar-
thritic rats after oral administration of HLXL or another single-
herb extract (e.g., Angelica pubescens extract or Notopterygium
incisum extract) have revealed interesting information about
the pharmacokinetic profile of the anti-inflammatory bioactive
components of HLXL [32]. Refined biochemical approaches such
as ultra performance liquid chromatography-tandemmass spec-
trometry (UPLC-MS/MS) were employed to measure bioactive
Fig. 1 – A schematic overview of the immunological,
biochemical and molecular biological effector mechanisms
that mediate the anti-arthritic activity of herbal products.
Herbal extracts and their bioactive components can
intervene at multiple steps in the pathogenesis of adjuvant
arthritis. The processes/pathways affected by herbal
products include cellular (T and B cells) and humoral
(antibody) immune responses, cytokine response/balance,
alterations in chemokines and chemokine receptors,
balance between pathogenic (Th17) and protective (Treg)
cells, balance among mediators of bone remodeling, and
changes in gene expression. The net effect of these
changes induced by herbal treatment is the suppression of
the disease-related processes in autoimmune arthritis.
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ingredients of herbal extracts in rat serum after oral feeding
of the herbal extract. For example, seven coumarins that
represent bioactive components of HLXL were tested in rat
plasma. Normal (control) and arthritic rats displayed signifi-
cant differences in the pharmacokinetic profiles of the analytes
tested. Similar differences in normal and arthritic rats were
observed in a another study by the same investigators using
a different herbal extract compared with HLXL [33]. In that study,
comparative pharmacokinetics of bioactive components shared
between HLXL and Boswellia serrata extract was studied in
normal and arthritic rats. The bioactive components in-
cluded two boswellic acids.Additional insights were gained from
this study in that the absorption of the two boswellic acids was
much higher in the case of HLXL compared with Boswellia serrata
extract alone. These results suggest synergism among com-
ponent herbs in the multi-herbal HLXL, which consists of 11
different herbs. The scientific evidence presented above vali-
dates an important theme ofTCM that the efficacy of an herbal
formula (e.g., HLXL) is superior to that of a single herb or its
compound,when used for the treatment of a particular disease,
in this case, inflammatory arthritis.
2.2. Celastrus
Celastrus is a TCM, which has been used for many decades for
the treatment of inflammatory diseases including arthritis.We
tested an ethanol fraction of Celastrus aculeatus Merr. HPLC
analysis revealed certain key components of Celastrus [34–39]
such as triterpenes (e.g., celastrol, celasdin C), flavonoids (e.g.,
epiafzelechin), and sesquiterpenes (e.g., orbiculin F) [22,26].
Celastrus was administered to arthritic rats at a dose of 1.5–
3 g/kg/day orally by gavage. Treatment was started at arthritis
onset and continued throughout the course of arthritis until
rats were sacrificed. Immunological, biochemical and molecu-
lar testing of various arthritis-related pathways were performed
as described above for HLXL.
Celastrus extract reduced the severity of clinical and
histological parameters of arthritis [22,26]. Major effect of
Celastrus on cytokines was on anti-inflammatory cytokine
IL-10, which was increased compared to that in controls.
Pro-inflammatory cytokine interferon-γ (IFN-γ) was mostly
unchanged, but indirectly this resulted in an altered ratio of
anti- vs. pro-inflammatory cytokines. The levels of nitric
oxide (NO) in serum and supernate of lymph node cells
(LNC) in Celastrus-treated rats were found to be reduced
compared to that of control rats. Surprisingly, anti-Bhsp65
antibodies were increased in Celastrus-treated rats com-
pared to controls [21]. We proposed that these antibodies in
Celastrus-treated rats include a subset that is protective
against arthritis. In our follow-up studies [22,26], we tested
additional pro-inflammatory cytokines, namely, IL-1β, IL-6,
IL-17, and IL-18.All these cytokines were inhibited by Celastrus.
Surprisingly, tumor necrosis factor-α (TNF-α) level was in-
creased and the reasons for that change were not fully clear.
In our other study focused on bone remodeling in arthritis,
we observed that Celastrus reduced the mediators of bone
damage such as MMP-9, RANKL, GM-CSF (granulocyte macro-
phage colony-stimulating factor), and OPN [26]. Furthermore,
gene chip analysis revealed a distinct pattern of changes in
several genes involved in immune response, cell prolifera-
tion, apoptosis, and cell signaling [40]. Comparison of Celastrus-
treated andWater-treated rats at the onset of AA revealed 84
differentially expressed genes (DEG) (2 upregulated, 82
downregulated) that were uniquely altered in Celastrus-
treated group.Water-treated group showed 8 DEG (6 upregulated,
2 downregulated) that were unique to that group. In addi-
tion, Celastrus-treated andWater-treated rats shared 20 genes
(6 upregulated, 14 downregulated).
Bai et al. tested an ethyl acetate extract from C. aculeatus
Merr in the rat AA model [41]. This treatment suppressed both
clinical arthritis and synovial inflammation.Through system-
atic examination of the mechanisms, it was shown that
Celastrus treatment increased the apoptosis of synoviocytes
and peripheral lymphocytes, and facilitated the induction of
CD4+CD25+Foxp3+ regulatory T cells. In a study using a dif-
ferent type of celastrus, namely, Celastrus orbiculatus, methanol
extract of that herb was tested in the chimeric SCID-HuRAg
model of human RA [42]. In this model, severe combined im-
munodeficient (SCID) mice were used, and the articular
synovium from RA patient (test) or normal articular cartilage
(control) was co-implanted subcutaneously into the back of
mice. Treatment with celastrus extract caused significant re-
duction in synovial hyperplasia and cartilage erosion. Serum
level of TNF-α was also reduced.
2.3. Green tea
Green tea is a popular beverage in several Asian countries, and
its consumption is gradually increasing in other parts of the
world. Besides several health maintenance benefits of green
tea, there is great interest in exploring its therapeutic ben-
efits in inflammatory and autoimmune diseases and cancer
[17].We tested an extract of Camellia sinensis containing the poly-
phenolic fraction of green tea (PGT) for its anti-arthritic activity
[28]. This extract contained the major ingredients including
epicatechin (EC), epigallocatechin (EGC), EC-3-O-gallate (ECG),
and EGC-3-O-gallate (EGCG). Rats were immunized with heat-
killed Mtb for induction of arthritis.Thereafter, rats were orally
fed green tea polyphenolic extract in water (8–12 g/L) for
1–3 weeks before disease induction [28]. The extract was fed
daily in water until the day of Mtb injection for induction of
arthritis.Thereafter, rats were followed regularly.Arthritic scores
were recorded and tissues were harvested for immunological
tests. After pilot testing as described above, we selected 8 g/L
dose and a feeding period of 2 weeks for detailed mechanis-
tic study. We observed that green tea extract inhibited the
development of clinical arthritis, reduced pro-inflammatory
cytokine IL-17 but not IFN-γ production, increased anti-
inflammatory cytokine IL-10 but not IL-4 production, and
suppressed serum levels of total immunoglobulins (Ig) as well
as IgG2a subset of antibodies against Bhsp65 [28]. Thus, green
tea given orally protected Lewis rats against development and
progression of arthritis.
The beneficial effect of green tea in arthritis has also been
demonstrated in another experimental model of RA, namely,
the mouse collagen-induced arthritis (CIA) model [43]. Feeding
a polyphenolic fraction of green tea to arthritic mice sup-
pressed clinical and histological features of arthritis. This
reduction in clinical arthritis was associated with significant
decrease in various mediators of inflammation such as IFN-γ,
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TNF-α, and cyclooxygenase-2 (COX-2) in the joints of ar-
thritic mice. Also reduced were serum levels of antibodies to
the disease-related antigen, type II collagen. Ahmed et al.
reported in a study focused on mechanistic aspect of the
anti-inflammatory activity of green tea that EGCG induces
alternative splicing of gp130 mRNA, which results in in-
creased production of soluble gp130 [44]. This in turn inhibits
IL-1-induced IL-6 production and trans-signaling, but reduces
IL-6/IL-6 receptor-induced MMP-2 production in synovial fi-
broblasts. Another study but using the rat CIA model of RA
was focused on the oxidant/anti-oxidant system [45]. That
study included testing of the levels of lipid peroxides, nitric
oxide, ceruloplasmin, superoxide dismutase, uric acid, gluta-
thione, prostaglandin E2, copper and zinc in the plasma of
green tea extract-treated rats compared with control rats
[45]. The results revealed that green tea extract was able to
reset the dysregulated oxidant/ anti-oxidant system in arthri-
tis, and thereby green tea might offer benefit against arthritis
and its complications in RA patients.
Marotte et al. tested green tea extract in the rat AA model
for its clinical effects and mechanisms of action against ar-
thritis [46]. The clinical disease was reduced, though the effect
was not very marked. In addition, there was a decrease in the
level of chemokines MCP-1 and GROα, but increased expres-
sion of chemokine receptors CCR-1, -2, -5 and CXCR1 in the
joints of green tea extract-treated rats compared with control
rats.The in vivo results were validated by in vitro culture system
of human RA fibroblasts treated with IL-1. Another study com-
paring the relative efficacy of green tea extract and black tea
extract in the rat AA model showed that green tea was more
effective in suppressing arthritis than black tea [47]. Further-
more, the effect of high dose of green tea extract was
comparable to that of the allopathic drug indomethacin. Green
tea treatment reduced systemic pro-inflammatory cytokines,
which play a vital role in arthritis pathogenesis. The bioactive
component of green tea, EGCG, was also tested on the IL-1 re-
ceptor antagonist knockout (IL-1RaKO) model of RA [48]. EGCG
treatment showed protection against clinical arthritis and joint
destruction. The latter was owing to the anti-osteoclastic ac-
tivity of EGCG. Examination of the mechanisms of action of
EGCG revealed multiple pathways that were influenced.These
included inhibition of expression of pro-inflammatory cytokines
and oxidative stress proteins. Also inhibited were biochemi-
cal pathways involving phosphor-signal transducer and activator
of transcription 3 (p-STAT3), mammalian target of rapamycin
(mTOR) and hypoxia-inducible factor-1α (HIF-1α), which are in-
volved in Th17/Treg differentiation. This is evident from the
reduced Th17/Treg ratio in the spleen of EGCG-treated mice
compared with control mice.
3. Anti-arthritic activity of purified herbal
compound, Celastrol
Following the experimental plan described above for Celastrus
extract, we tested one of the purified bioactive compounds of
Celastrus, namely Celastrol, in arthritic Lewis rats [22]. Celastrol
is a triterpenoid, which along with other triterpenoids has been
shown to possess anti-oxidant, anti-inflammatory, and anti-
cancer activities [16,49]. In our study, rats were treated with
Celastrol intraperitoneally (1 mg/kg/d) beginning at the onset
of arthritis and continuing either for the entire duration of ex-
periment or for about 10 days after initial injection in different
experiments. Celastrol showed potent anti-arthritis activity [22].
In addition to inhibiting pro-inflammatory cytokines (IFN-γ, IL-
1β, IL-6, IL-17) and chemokines (RANTES and MIP-1α), Celastrol
reduced anti-Bhsp65 and anti-cyclic ciltrullinated peptide (aCCP)
antibody levels compared to control rats [22]. Nanjundaiah et al.
examined the effect of celastrol on immune system-bone in-
teraction (osteoimmunology), and showed that celastrol
treatment of arthritic rats inhibited RANKL, but increased OPG,
thus altering the RANKL/OPG ratio [26].Also reduced were MMP-
9, GM-CSF and OPN. A new set of parameters tested with
Celastrol was the ratio between Th17 and Treg in the target
organ, the joints [27]. Interestingly, celastrol treatment reduced
Th17 levels, but increased Treg levels in the joints of Celastrol-
treated rats compared with control rats. Furthermore, in an in
vitro system, Celastrol inhibited the differentiation of Th17, but
promoted the differentiation ofTreg [27].Thus, Celastrol altered
the Th17/Treg ratio in vitro as well as in vivo. These changes
were in part attributed to Celastrol-induced inhibition of
p-STAT3. Gene chip analysis of the draining lymph node cells
of celastrol-treated vs. vehicle-treated rats showed that 14 genes
(12 upregulated, 2 downregulated) were uniquely altered in their
expression following celastrol treatment, whereas 57 genes (38
upregulated, 19 downregulated) showed differential expres-
sion in vehicle-treated rats [50]. Furthermore, another 19 genes
(7 upregulated, 12 downregulated) were shared between
celastrol-treated and vehicle-treated rats. Altered genes were
related to the immune cells, cellular proliferation and inflam-
matory responses.
Celastrol is also known as tripterine. In a study in the rat
AA model, it was shown that tripterine had anti-arthritic ac-
tivity [51]. Intragastric administration of tripterine suppressed
paw swelling and bone damage in ongoing AA. This was as-
sociated with reduced levels of mRNA expression of IL-1 and
TNF-α in the joints as tested using paw homogenates. Cascao
et al. showed that Celastrol inhibits the production of IL-1 and
TNF-α in vitro, as well as inhibits clinical arthritis in the rat
AAmodel [52].Authors concluded that Celastrol possesses anti-
inflammatory and anti-proliferative properties, and further
suggested that Celastrol might constitute a potential thera-
peutic for RA.
Another study was focused on the effect of celastrol on IL-
17-induced migration and invasion of fibroblast-like
synoviocytes (FLSs), which play an important role in the patho-
genesis of RA [53]. Celastrol treatment suppressed IL-17-
induced migration and invasion of RA-FLSs as well as IL-17-
induced MMP-9 and its proteolytic activity. Furthermore,
celastrol reduced NF-kB-mediated MMP-9 expression. Gan et al.
tested celastrol in the mouse CIA model, with particular em-
phasis on bone erosion [54]. Celastrol treatment suppressed
both clinical arthritis and bone damage. In addition, celastrol
inhibited the formation and function of osteoclasts. For
example, there was a reduction of osteoclasts in the joints, of
serum tartrate-resistant acid phosphatase, and of the expres-
sion of specific osteoclastic genes and transcriptional factors.
It was suggested that celastrol could directly inhibit osteo-
clast formation and function.
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4. Conclusions
Plant-derived natural products offer a vital and promising re-
source for new therapeutic agents for RA and other
autoimmune diseases. Practitioners of the traditional systems
of medicine prefer to use herbal extracts, either singly or in a
formulation using multiple herbs. However, as part of its drug
discovery process, the pharmaceutical industry frequently so-
licits purified herbal compounds which possess bioactivity that
replicates, albeit exceeds, the bioactivity of the parental herbal
extract.An unforeseen but not unexpected scenario in that case
is that the purified compounds might be more potent, but at
the same time they also might be more toxic, than the whole
natural extract. Carefully planned dosing studies with suit-
able modifications in the product following an active
collaboration between the academia and the industry would
help further expand the applications of natural products in the
treatment of autoimmune and other disorders. Similarly, there
is a need for practitioners of the mainstream (allopathic) medi-
cine and those of CAM to work together on the use of these
products for the treatment of various diseases. This is impor-
tant to anticipate and manage unwanted interactions between
conventional (allopathic) and CAM products being used con-
currently by patients with autoimmunity and other diseases.
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